You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, October 2020
|
| DOI | 10.1007/s10549-020-05978-8 |
| Pubmed ID | |
| Authors |
Gwen M. H. E. Dackus, Katarzyna Jóźwiak, Elsken van der Wall, Paul J. van Diest, Michael Hauptmann, Sabine Siesling, Gabe S. Sonke, Sabine C. Linn |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 18% |
| Unspecified | 3 | 11% |
| Other | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Student > Doctoral Student | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 13 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 14% |
| Unspecified | 3 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Economics, Econometrics and Finance | 1 | 4% |
| Business, Management and Accounting | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 16 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2020.
All research outputs
#20,662,373
of 23,257,423 outputs
Outputs from Breast Cancer Research and Treatment
#4,143
of 4,701 outputs
Outputs of similar age
#359,148
of 420,386 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#53
of 60 outputs
Altmetric has tracked 23,257,423 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,701 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,386 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.